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Abstract
Background: Coenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative
phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity
in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of
varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress.
Methods: We performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated,
and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of
F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations
were measured to determine dose, concentration and response relationships.
Results: Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in
a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations
decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs.
baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not
change during the study.
Conclusions: CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated
in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent
manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients
receiving hemodialysis.
Trial Registration: This clinical trial was registered on clinicaltrials.gov [NCT00908297] on May 21, 2009.
Keywords: Clinical study, Coenzyme Q10, Hemodialysis, Kidney disease, Oxidative stress
Background
Five hundred thousand patients in the United States receive
maintenance hemodialysis (MHD) for end-stage renal dis-
ease (ESRD) [1]. Life expectancies for MHD patients are
17–34 % less than those of the general population [2]. Some
of this excess mortality may be attributable to an increased
risk of cardiovascular disease as a result of increased
oxidative stress [3, 4]. Oxidative stress can originate from
multiple sources, including the decoupling of the electron
transport chain in the mitochondria and inflammation-
mediated production of superoxide via NADPH-oxidase
and resulting altered oxygen handling capacity.
Coenzyme Q10 (CoQ10) is a required component of
the mitochondrial electron transport chain, where it
transfers electrons from complexes 1 and 2 to complex
3. Reduction and oxidation of CoQ10 also reduces lipid
radicals and oxidizes superoxide. CoQ10 depletion leads
to inefficient electron transport, increased reactive
oxygen species (ROS) production, decreased adenosine
triphosphate (ATP) production, and altered mitochondrial
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membrane potential [5]. CoQ10 treatment, on the other
hand, improves mitochondrial coupling of respiration to
oxidative phosphorylation, decreases superoxide produc-
tion in endothelial cells, and may improve functional car-
diac capacity in patients with congestive heart failure [6].
In addition to the effects on mitochondrial transport,
CoQ10 also exerts global antioxidant effects, with the re-
duced form able to react directly with free radicals,
wherein it is converted to the oxidized form [7]. For these
reasons, CoQ10 is frequently administered as a dietary
supplement in alternative and complementary therapy,
but no studies have examined high dose CoQ10 tolerability
and efficacy in dialysis patients, a population with in-
creased oxidative stress [8, 9]. F2-isoprostane and isofuran
concentrations, products of non-enzymatic arachidonic
acid peroxidation, are considered one of the most reliable
approaches for assessing systemic oxidative stress in vivo
[10]. The formation of F2-isoprostanes and isofurans is
differentially regulated by oxygen tension; the formation
of F2-isoprostanes is favored at low oxygen tensions
whereas the formation of isofurans is favored at high oxy-
gen tensions, as occurs in the setting of mitochondrial
dysfunction [11, 12]. Plasma F2-isoprostane concentra-
tions have been shown to be two to four times higher in
dialysis patients than in age- and gender- matched healthy
subjects [13, 14], consistent with the increased oxidative
burden in this population. Plasma isofuran concentrations
have not previously been reported in dialysis patients.
The present study tested the hypothesis that oral
CoQ10 administration is safe, well-tolerated, and de-
creases oxidative stress in MHD patients, with the add-
itional goals of determining the maximum well-tolerated
dose of CoQ10.
Methods
Study design
We performed an open label, dose-escalation study
(Fig. 1) to evaluate the safety and tolerability of CoQ10
in HD patients using a commercially available CoQ10
chewable wafer (Vitaline Formulas, Wilsonville, OR).
Study population
End stage renal disease patients, between the ages of 18
and 85 years, receiving thrice weekly dialysis using high-
flux dialyzers, with a life expectancy of >1 year, and a
baseline plasma F2-isoprostane concentration greater than
or equal to 50 pg/ml were eligible for study. Twenty
MHD subjects were enrolled from two university medical
centers. All subjects provided written informed consent
that was approved by the University of Washington and
the Vanderbilt University Institutional Review Boards. All
study procedures were conducted in accordance with
Helsinki Declaration of 1975 (as revised in 2000).
Subject exclusion criteria included: history of poor
adherence to MHD or medical regimen, AIDS (HIV
seropositivity was not an exclusion criteria), active ma-
lignancy excluding basal cell carcinoma of the skin,
gastrointestinal dysfunction requiring parenteral nutri-
tion, kidney transplant < 6 months prior to study entry
or anticipated live donor kidney transplant, current use
of vitamin E supplements > 60 IU/day, vitamin C sup-
plements > 150 mg/day, current use of l-carnitine or
other antioxidant or nutritional supplements, initiation
of hemodialysis within 90 days prior to study enroll-
ment, hospitalization within the past 60 days, dialysis
with a tunneled catheter as a temporary vascular access,
and a history of a major atherosclerotic event (defined
as myocardial infarction, urgent target-vessel revascu-
larization, coronary artery bypass surgery, or stroke)
within six months.
Plasma samples from healthy control subjects (n = 10)
were randomly selected from the Kidney Research Insti-
tute biorepository. Healthy control subjects had normal
kidney function and were not taking statin medications.
Healthy control subjects were not matched for age, race,
or gender with subjects receiving CoQ10 supplementa-
tion. The control subjects were younger, more likely to
be female, and less likely to be taking a statin than the
dialysis subjects.
With a sample size of 20 subjects, we predicted that
we would have at least 94 % power to detect a 45 %
change in plasma F2-isoprostane levels after CoQ10 ad-
ministration (estimated mean plasma F2-isoprostane
concentrations in MHD patients = 96 pg/mL, with a
standard deviation of 49 pg/mL), assuming a 2-sided,
0.05 alpha level using a paired t-test approach.
CoQ10 dose escalation
Subjects were administered 300 mg CoQ10 for 14 days
and then 600, 1200, and 1800 mg CoQ10 daily, each for
14 days. Subjects returned to the clinic at the end of
each dosing period and spontaneously reported adverse
events were recorded at every visit. Blood samples were
collected at baseline, and after each 14-day course of
treatment for determination of comprehensive metabolic
Fig. 1 CoQ10 dose escalation study design. *Measurement of plasma
CoQ10, comprehensive metabolic panel, creatine phosphokinase,
and oxidative stress biomarkers
Yeung et al. BMC Nephrology  (2015) 16:183 Page 2 of 8
panel (electrolytes, blood urea nitrogen, creatinine, glu-
cose, albumin, total protein, calcium, alkaline phosphat-
ase, ALT, AST, total bilirubin), creatine phosphokinase
(CPK), F2-isoprostane and isofuran concentrations.
Blood samples for High Density Lipoprotein (HDL)
apoA-1 Met(O) were collected at baseline and following
1200 mg dosing period. All blood samples were imme-
diately chilled, and then centrifuged within one hour of
collection at 2500 RPM, 4 °C, for 15 min. Plasma (hepa-
rinized) was removed and stored at −80 °C until ana-
lysis. Ten subjects participated in an additional study in
which CoQ10 levels were measured prior to and imme-
diately following standard HD to assess the effect of
HD on plasma CoQ10 concentrations. CoQ10 concen-
trations were also measured in the plasma of the 10
unmatched healthy control subjects. Access to the
remaining samples may be granted by contacting the
corresponding author.
Assays
For CoQ10 measurement, plasma samples were thawed
on ice, and a 100 μl aliquot was mixed with 200 μL ice
cold 1-propanol containing Coenzyme Q9 (CoQ9) and
CoQ9H2 as internal standards. Precipitated proteins
were removed by cold centrifugation, and the super-
natant injected directly onto the LC-MS/MS for analysis.
Samples in the autosampler were held at 4 °C until injec-
tion. Chromatography of the analytes was accomplished
using an Agilent 1200s-series LC system equipped with
a Zorbax SB-C18 column (30 mm × 2.1 mm × 3.5 μM
particle size) that was maintained at 40 °C. The mobile
phase consisted of a binary gradient of methanol and
5 mM ammonium formate pumped at a flow rate of
0.8 mL/min. The MS/MS was operated in positive ESI
mode with nitrogen as drying gas at a flow of 10 L/min
and 350 °C, and with nitrogen nebulizer gas set at
35 psi. The monitored transitions for CoQ10H2, CoQ10,
CoQ9H2 and CoQ9 were 882.7→ 197.1, 863.7→ 197.1,
814.7→ 197.1, and 795.6→ 197.1 respectively. Method
validation, including stability of analytes and internal
standards, and comparisons to established methods are
detailed in reference [15].
For F2-isoprostane and isofuran measurements, in-
ternal standard [2H4]-15-F2T-isoprostane was added to
each plasma sample prior to C-18 and silica solid phase
extraction, thin layer chromatography, and derivatization
to penta-fluorobenzyl ester, trimethylsilyl ether deriva-
tive [16]. GC/NICI-MS was performed (Agilent 5973)
using 15 m x 0.25 μm thick fused silica capillary col-
umns (J and W Scientific). The major ion generated was
m/z 569 carboxylate anion [M-181 (M-CH2C6F5)]. The
corresponding ion generated from the [2H4]-15-F2T-iso-
prostane internal standard was m/z 573, and the iso-
furan ion was m/z 585.
For Met(O) measurement, HDL was isolated, digested
and oxidation of Met residues in apoA-I of HDL was
quantified by isotope dilution mass spectrometry (MS)
and selective reaction monitoring (SRM) on a Thermo
TSQ Vantage coupled to a Waters nanoACQUITY
UltraPerformance liquid chromatography system as pre-
viously described [17].
Comprehensive metabolic panel and CPK measurements
were performed in the CLIA-certified hospital laboratories
of University of Washington Medical Center and Vanderbilt
University Medical Center. Plasma IL-6 was measured
using a commercial kit according to the manufacturer’s
protocol (R&D Systems, Minneapolis MN).
Data analysis
Mean baseline values and change from baseline were de-
termined for CoQ10 concentrations, all safety endpoints
(comprehensive metabolic panel, CPK, electrocardio-
gram results, physical examination findings), and efficacy
measures (oxidative stress biomarker concentrations).
Each of these parameters was analyzed via one-way re-
peated measures analysis of variance to determine the
presence or absence of dose-related differences. In
addition, mixed effects modeling was used to test the ef-
fect of increased CoQ10 dose and duration with fixed ef-
fect of time (dose), random subject effect, and an
unstructured repeated covariance type. Study subject
concentrations of CoQ10, F2-isoprostanes, and isofurans
were also compared to concentrations in non-dialysis
historical control subjects. The primary analysis included
all subjects. Subgroup analyses were conducted in statin
treated (n = 6) and non-statin treated (n = 14) subjects.
Spearman’s correlation coefficients were used to assess
correlations between plasma CoQ10 concentrations and
oxidative stress biomarkers. Two-tailed P-values ≤ 0.05
were considered significant in all analyses. When appro-
priate, corrections were made for multiple comparisons.
Statistical analysis was conducted using STATA 11.0 and
SAS 9.1 (SAS Institute, Cary, NC, USA). Data is
expressed as mean ± standard deviation unless otherwise
specified.
Results
Twenty subjects were recruited for the study, fifteen of
whom completed the entire dose escalation protocol
(Fig. 2). The mean age of subjects was 58 years with 8
females studied. Average length of time on dialysis was
8.0 ± 8.9 years (range 0.7 to 29.4 years). Seven subjects
were taking statin medications. Three subjects discontin-
ued study participation due to abdominal pain or nausea;
one during the 300 mg/day period, one during the
1200 mg/day period, and one after the 1800 mg/day
period. One subject discontinued participation after an
unrelated elevation in INR (international normalized
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ratio), and one subject discontinued participation after
damaging a tooth from chewing the CoQ10 wafer. Three
subjects reported stomach discomfort at the 1800 mg/day
dose but completed the study. One subject was found ex-
pired at home 22 days after completing the study. This
death was attributed to natural causes and was deemed to
be unrelated to study participation.
Plasma CoQ10 concentrations
Mean plasma total CoQ10 levels at baseline (prior to a
mid-week dialysis session) were 704 ± 286 ng/mL, sig-
nificantly lower than CoQ10 levels in healthy control pa-
tients (1385 ± 640 ng/mL, P = 0.0014). Plasma CoQ10
concentrations increased linearly with escalation of
CoQ10 dose (Fig. 3). At the end of the 1800 mg/day dosing
period, total CoQ10 plasma concentrations averaged 4032
± 1637 ng/mL (P < 0.001 compared to baseline and to
healthy controls). The CoQ10 redox ratio (CoQ10H2:CoQ10)
increased from 14 ± 7.4 at baseline to 22 ± 9 after supple-
mentation (P = 0.013). Despite this increase, the redox ratio
remained significantly less than that observed in healthy
controls (41 ± 12, P < 0.001, Fig. 3). Statin using (n = 6) and
non-using (n = 14) subjects had similar plasma concentra-
tions of CoQ10 and CoQ10H2: CoQ10 ratios at baseline and
at the end of the study (3438 ± 1899 ng/mL, redox ratio
25.7 ± 9.4 in statin users vs. 4080 ± 1467 ng/ml, redox ratio
18.8 ± 6.5 in statin non-users at the end of the study; P =
0.31 for CoQ10 plasma concentration, P = 0.10 for redox
ratio). Plasma CoQ10 levels measured just before and im-
mediately after hemodialysis did not differ significantly
(Fig. 4), indicating that hemodialysis does not clear the lipo-
philic CoQ10 from blood or acutely alter the circulating
pool of CoQ10 (p = 0.72).
Effects of CoQ10 supplementation on F2-isoprostanes and
Isofurans
Baseline F2-isoprostane and isofuran levels were 66.9 ±
24.9 pg/ml and 141 ± 67.5 pg/ml respectively, notably
higher than levels observed in 140 historic control pa-
tients not on dialysis (42.5 ± 32.6 pg/mL F2-isoprostanes,
P = 0.002 and 57.0 ± 52.9 pg/mL isofurans, P < 0.001)
[18]. During CoQ10 dose escalation, F2-isoprostane con-
centrations did not change compared to baseline (P =
0.92). Plasma isofuran concentrations, however, de-
creased following the 1200 mg (112.8 ± 72.9 pg/ml) and
1800 mg (72.8 ± 37.5 pg/ml) dosing periods (P < 0.001,
effect of dose escalation on isofurans, Fig. 5a-c). Isofuran
concentrations following 1800 mg/day CoQ10 dosing
were 45.1 ± 8.1 % lower than baseline concentrations
(P = 0.003). In addition, the ratio of isofuran concen-
trations to F2-isoprostane concentrations decreased
from 2.56 ± 2.26 to 1.07 ± 0.56 during CoQ10 dose es-
calation (P = 0.01), a ratio similar to that observed in
non-dialysis control subjects (1.53 ± 1.31, P =0.16).
Consistent with the effect of CoQ10 dose escalation on
Fig. 2 Overview of study subject participation and study withdrawal
Fig. 3 Effect of Coenzyme Q10 supplementation on plasma concentrations of total CoQ10 (a) and CoQ10(H2):CoQ10 ratios (b) (mean ± SD) in
study subjects and unmatched healthy controls. Sample numbers for baseline (0 mg), 300 mg, 600 mg, 1200 mg, 1800 mg, and healthy controls
were 20, 19, 19, 18, 15, and 10, respectively
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isofuran concentrations and isofuran:F2-isoprostane
ratios, plasma concentrations of CoQ10 were inversely
correlated with isofuran concentrations and isofur-
an:F2-isoprostane ratios (CoQ10 isofuran correlation
coefficient = −0.29, P = 0.02; CoQ10 isofurans:F2-isopros-
tanes ratio correlation coefficient = −0.28, P = 0.02). There
was no correlation between plasma concentrations of F2-
isoprostanes and plasma CoQ10 concentrations (P = 0.62,
Fig. 5d–f ).
Effects of CoQ10 supplementation on interleukin-6 (IL-6)
Baseline mean IL-6 concentration was 11.2 ± 8.1 ng/ml.
During CoQ10 dose escalation, IL-6 levels did not
change significantly (15.7 ± 18.9 ng/mL at 1800 mg
CoQ10, P = 0.56), and no association was observed be-
tween IL-6 levels and plasma CoQ10 levels (P = 0.20)
(Fig. 6a and b).
Effects of CoQ10 supplementation on apoprotein A-1
(apoA-1) methionine oxidation (Met(O))
Oxidation of Met residues 86, 112, or148 in apoA-1 was
not different following the 1200 mg CoQ10 dosing
period, as compared to baseline apoA-1 Met oxidation
(Fig. 7).
Safety and tolerability
Six subjects complained of nausea and abdominal pain
during the course of the study. One of these subjects
made this complaint during the 300 mg dosing period,
two following the 1200 mg dosing period, and three fol-
lowing the 1800 mg dosing period. Three of these sub-
jects discontinued CoQ10 treatment, but the other three
subjects continued taking CoQ10 despite reporting
nausea and abdominal pain. Gastrointestinal complaints
resolved after discontinuation of CoQ10. One subject
(non-statin user) was found to have a CPK concentra-
tion of 2918 U/L following the 600 mg dosing period
but was known to participate in competitive athletics
and did not report any myalgia. He remained in the
study and following the 1200 mg period his CPK level
Fig. 4 Effect of hemodialysis (HD) on plasma concentrations of
CoQ10 in study subjects administered 1800 mg of CoQ10 for 14 days
(n = 10). Dark bars indicate total CoQ10 levels prior to standard
hemodialysis treatment, lighter bars are following hemodialysis. Error
bars indicate SD of the means (paired T-test for means p = 0.72)
Fig. 5 Effect of CoQ10 dose escalation (a–c) and total CoQ10 plasma concentrations (d–f) on plasma concentrations of F2-isoprostanes, isofurans,
and isofuran:F2-isoprostane ratios
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returned to 311 U/L (similar to his baseline concentra-
tion). Overall mean CPK concentrations did not change
in the study cohort during CoQ10 dose escalation.
CoQ10 dose escalation did not affect blood pressure.
Discussion
In this dose escalation study we found oral administra-
tion of CoQ10 to be safe and well-tolerated at doses
under 1800 mg/day. Three of the 5 of the adverse events
occurred in subjects receiving more than 1200 mg daily,
and only 3 of 6 subjects experiencing adverse effects
withdrew from the study. Plasma CoQ10 levels increased
linearly with dose, suggesting that the chewable wafer
used in this study has consistent bioavailability. In
addition, our data indicated that CoQ10 may reduce sys-
temic oxidative stress in MHD patients in a dose-
dependent manner.
CoQ10 has been studied extensively in healthy popula-
tions and patients with cognitive impairment. In these
populations, CoQ10 has also been well tolerated. MHD
patients are subject to elevated inflammation and oxida-
tive stress as a result of ineffective clearance of uremic
toxins, especially middle molecules (molecular weight
300–20,000 Da) [19] that include circulating cytokines.
We have previously observed that MHD patients have
63 % higher concentrations of F2-isoprostanes than
healthy controls [9], and a reduction in oxidative stress
has been associated with better outcomes in MHD pa-
tients. A study by Sakata et al. evaluated the efficacy of a
low oral dose of CoQ10 (100 mg daily) for 6 months in
Japanese MHD patients and demonstrated that CoQ10
partially suppressed advanced oxidation protein product
accumulation [20]. Singh et al. also demonstrated a
benefit of CoQ10 in CKD; subjects who received 60 mg
of CoQ10 three times daily had reduced serum creatinine
and urea concentrations, increased creatinine clearance,
and urine output compared with controls [21]. The
doses used in Sakata and Singh studies were lower than
those typically used in other studies (300–1200 mg
daily); higher doses of CoQ10 may be required to sub-
stantively reduce oxidative stress in the MHD popula-
tion. The present study is the first study to evaluate the
safety and tolerability of high dose CoQ10 in a popula-
tion receiving MHD.
CoQ10 dose escalation reduced plasma concentrations
of isofurans but not F2-isoprostanes or HDL apoA-1
Met oxidation. To our knowledge, this is the first in vivo
study in any patient population to demonstrate that
plasma concentrations of isofurans are modifiable by any
therapeutic antioxidant strategy. Our results are consist-
ent with previously published unrelated studies, that
show that plasma F2-isoprostane concentrations are sig-
nificantly increased in patients undergoing maintenance
HD compared with healthy subjects (published healthy
controls: 37.6 pg/mL [14], subjects at baseline in this
study: 65 pg/mL, after 1800 mg CoQ10: 72 pg/mL). In
contrast, our subjects who also had elevated concentra-
tions of isofurans at baseline (0.145 ng/mL) compared
with healthy subjects (0.071 ng/mL) [22] demonstrated
near-normalization after maximal supplementation
(0.078 ng/mL). The generation of isofurans and F2-iso-
prostanes is regulated by the availability of oxygen; in
cellular environments with relatively low oxygen avail-
ability, F2-isoprostanes are generated from ROS, while
Fig. 6 Effect of CoQ10 dose escalation (a) and total CoQ10 plasma concentrations (b) on plasma concentrations of interleukin-6
Fig. 7 Effect of CoQ10 supplementation (following 1200 mg dosing
period) on levels of oxidized methionine (mean ± SD) in
apolipoprotein A-I of high density lipoprotein (all p-values > 0.5)
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isofurans are preferentially generated in environments
with relatively high oxygen availability. In vivo, isofuran
generation is observed during inhalation of high concen-
trations of oxygen in healthy subjects and in tissues with
low consumption of oxygen such as the substantia nigra
of Parkinson’s patients [11]. Mitochondrial dysfunction
observed in Parkinsonism or ESRD, may lead to high
cellular oxygen tension since dysfunctional mitochondria
consume little oxygen. In this environment ROS forma-
tion preferentially increases the generation of isofurans
but not F2-isoprostanes. CoQ10 transfers electrons from
complexes 1 and 2 to complex 3 in the mitochondrial
electron transport chain. The suppression of isofuran
generation observed with CoQ10 dose escalation is con-
sistent with the idea that CoQ10 improves mitochondrial
function in MHD patients and reduces the generation of
ROS.
In order to differentiate the effects of CoQ10 on
mitochondrial coupling versus direct antioxidant ef-
fect, we evaluated the effect of CoQ10 supplementation
on ApoA-1 Met oxidation, which is selective for
inflammation-mediated oxidative damage by myelo-
peroxidase (MPO). The lack of effect of CoQ10 escal-
ation on apoA-1 Met oxidation in circulating HDL
suggests the salutary effect of CoQ10 may be due to im-
proved local mitochondrial function rather than a sys-
temic anti-oxidant effect. The reduction of HDL-
associated lipid hydroperoxides to the corresponding
lipid hydroxides is responsible for specific oxidized
Met residues (Met(O) 86 and Met(O) 112) in apoA-I,
the major HDL protein [17]. In addition, hydrogen per-
oxide and hypochlorous acid (HOCl), a strong oxidant
produced by the phagocyte heme enzyme myeloperoxi-
dase may selectively oxidize Met112 and Met148 in
apoA-I [23, 24]. In addition to the lack of effect of
CoQ10 supplementation on ApoA-1 Met oxidation, no
significant change in IL-6, a pro-inflammatory cytokine
(11.2 ± 8.1 pg/mL at baseline; 15.7 ± 18.9 pg/mL at
study conclusion (p = 0.56), in comparison to unrelated
healthy controls with a median IL-6 concentration:
3.8 pg/mL) [25], was observed during this study, pro-
viding more presumptive evidence that the actions of
CoQ10 are not due to a global anti- inflammatory ef-
fect. Taken together, our observations support the hypoth-
esis that CoQ10 supplementation reduces mitochondrial
oxidative stress, rather than by increasing general antioxi-
dant or anti-inflammatory capacity. However, we cannot
rule out some contribution of general antioxidant effect to
the observed reduction in oxidative stress markers.
This study has several limitations that are inherent to
fixed-sequence dose escalation studies. The dosing de-
sign does not allow us to fully attribute the observed ef-
fect on markers of oxidative stress to escalated dose or
duration of CoQ10 supplementation and were unable to
control for the effects of disease progression during the
study. This study was conducted in patients undergoing
thrice weekly hemodialysis, and did not include patients
receiving alternate methods of dialysis, including peri-
toneal dialysis or daily dialysis. Since the exposures to
uremic toxins in patients receiving other types of dialysis
or dialytic regimens differ from our study population, we
are unable to generalize our findings to these other dia-
lysis regimens. The study examined relatively short-term
effects of CoQ10 administration. Longer term CoQ10
supplementation could have some safety concerns, as
CoQ10 could precipitate drug-drug interactions—in
animal studies, CoQ10 supplementation has been
shown to affect metabolism of theophylline [26], and
in vitro, affect transport by P-glycoprotein, an intes-
tinal drug transporter [27]. CoQ10 supplementation
could also alter the oral bioavailability of digoxin and
verapamil, both P-glycoprotein substrates.
In summary, CoQ10 appears to be safe and well toler-
ated in subjects receiving MHD and may reduce oxida-
tive stress by improving mitochondrial function. Further
studies are needed to investigate the potential metabolic
and clinical benefits associated with longer term CoQ10
supplementation.
Conclusions
Coenzyme Q10 supplementation improves mitochondrial
coupling of respiration to oxidative phosphorylation, and
decreases superoxide production in endothelial cells.
CoQ10 may be especially beneficial in patients undergo-
ing chronic hemodialysis, a population subject to in-
creased oxidative stress. This is the first in vivo study in
any patient population to demonstrate that plasma con-
centrations of isofurans are modifiable by any thera-
peutic antioxidant strategy and suggests that CoQ10 may
improve mitochondrial function and decrease oxidative
stress in patients receiving hemodialysis.
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